Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.54 |
| ▸ | JAK2 | O60674 | 5/20 | 0.54 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017271 | 1.00 | BRD4 (0.54) | BRD4JAK2PAK4PDPK1BRD2 | |
| SCHEMBL2016028 | 0.85 | PAK4 (0.47) | PAK4PDPK1 | |
| SCHEMBL2016025 | 0.85 | PAK4 (0.47) | PAK4PDPK1 | |
| SCHEMBL2021182 | 0.78 | BRD4 (0.52) | BRD4JAK2PAK4PDPK1BRD2 | |
| SCHEMBL2021185 | 0.78 | BRD4 (0.52) | BRD4JAK2PAK4PDPK1BRD2 | |
| SCHEMBL2018827 | 0.77 | BRD4 (0.50) | BRD4JAK2PAK4PDPK1BRD2 | |
| SCHEMBL2018828 | 0.77 | BRD4 (0.50) | BRD4JAK2PAK4PDPK1BRD2 | |
| SCHEMBL2018756 | 0.72 | JAK3 (0.43) | JAK2JAK3SCN9A | |
| SCHEMBL2018758 | 0.72 | JAK3 (0.43) | JAK2JAK3SCN9A | |
| SCHEMBL3961208 | 0.68 | JAK3 (0.66) | JAK2JAK3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | BRD4 338/4885JAK2 2/4885PAK4 603/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | BRD4 338/4885JAK2 2/4885PAK4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.